Dane E. Karr

2.4k total citations
29 papers, 1.5k citations indexed

About

Dane E. Karr is a scholar working on Spectroscopy, Molecular Biology and Genetics. According to data from OpenAlex, Dane E. Karr has authored 29 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Spectroscopy, 9 papers in Molecular Biology and 7 papers in Genetics. Recurrent topics in Dane E. Karr's work include Mass Spectrometry Techniques and Applications (9 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Analytical chemistry methods development (6 papers). Dane E. Karr is often cited by papers focused on Mass Spectrometry Techniques and Applications (9 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Analytical chemistry methods development (6 papers). Dane E. Karr collaborates with scholars based in United States, Australia and Canada. Dane E. Karr's co-authors include Paul O. Danis, Donald E. Schmidt, Robert Cass, Franz J. Mayer, Clifford H. Watson, A. Holle, Kevin M. Krause, C W Moss, Koné Kaniga and Ray Chang and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Macromolecules.

In The Last Decade

Dane E. Karr

29 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dane E. Karr United States 18 483 435 317 197 185 29 1.5k
Keiko Tabei United States 21 214 0.4× 710 1.6× 161 0.5× 146 0.7× 35 0.2× 32 1.2k
Aleš Štrancar Slovenia 37 998 2.1× 2.3k 5.2× 327 1.0× 61 0.3× 162 0.9× 123 3.6k
John Chapman United Kingdom 23 481 1.0× 264 0.6× 55 0.2× 34 0.2× 198 1.1× 80 1.3k
T. William Hutchens United States 30 1.0k 2.2× 1.5k 3.5× 91 0.3× 14 0.1× 124 0.7× 82 2.8k
Dominique J. Wiener United States 15 138 0.3× 470 1.1× 1.1k 3.3× 124 0.6× 9 0.0× 20 1.5k
Hugo D. Meiring Netherlands 23 493 1.0× 1.1k 2.6× 155 0.5× 25 0.1× 90 0.5× 57 2.1k
Matthew Zimmerman United States 26 64 0.1× 813 1.9× 1.5k 4.6× 181 0.9× 10 0.1× 57 2.4k
S. Jönsson Iceland 24 178 0.4× 718 1.7× 317 1.0× 41 0.2× 70 0.4× 45 1.8k
Lene Jakobsen Denmark 10 329 0.7× 574 1.3× 136 0.4× 29 0.1× 21 0.1× 13 1.0k
Ruchi Pandey United States 16 37 0.1× 549 1.3× 260 0.8× 361 1.8× 14 0.1× 28 1.6k

Countries citing papers authored by Dane E. Karr

Since Specialization
Citations

This map shows the geographic impact of Dane E. Karr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dane E. Karr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dane E. Karr more than expected).

Fields of papers citing papers by Dane E. Karr

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dane E. Karr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dane E. Karr. The network helps show where Dane E. Karr may publish in the future.

Co-authorship network of co-authors of Dane E. Karr

This figure shows the co-authorship network connecting the top 25 collaborators of Dane E. Karr. A scholar is included among the top collaborators of Dane E. Karr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dane E. Karr. Dane E. Karr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Owens, Timothy D., Patrick F. Smith, Andrew Redfern, et al.. (2021). Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168). Clinical and Translational Science. 15(2). 442–450. 36 indexed citations
2.
Robbins, Daniel, Mark Noviski, Ryan B. Rountree, et al.. (2021). Nx-5948, a Selective Degrader of BTK with Activity in Preclinical Models of Hematologic and Brain Malignancies. Blood. 138(Supplement 1). 2251–2251. 35 indexed citations
3.
Robbins, Daniel, Mark Noviski, Cristiana Guiducci, et al.. (2021). POS0006 NX-5948, A SELECTIVE DEGRADER OF BTK, SIGNIFICANTLY REDUCES INFLAMMATION IN A MODEL OF AUTOIMMUNE DISEASE. Annals of the Rheumatic Diseases. 80. 204–205. 5 indexed citations
4.
Venetsanakos, Eleni, Ken A. Brameld, Vernon T. Phan, et al.. (2017). The Irreversible Covalent Fibroblast Growth Factor Receptor Inhibitor PRN1371 Exhibits Sustained Inhibition of FGFR after Drug Clearance. Molecular Cancer Therapeutics. 16(12). 2668–2676. 22 indexed citations
5.
Langrish, Claire L., J. Michael Bradshaw, Timothy D. Owens, et al.. (2017). PRN1008, a Reversible Covalent BTK Inhibitor in Clinical Development for Immune Thrombocytopenic Purpura. Blood. 130. 1052–1052. 15 indexed citations
6.
Piha‐Paul, Sarina A., Cinta Hierro, Valentina Boni, et al.. (2017). A phase 1, multicenter, dose-escalation study of PRN1371, an irreversible covalent FGFR1-4 kinase inhibitor, in patients with advanced solid tumors, followed by expansion cohorts in patients with FGFR genetic alterations.. Journal of Clinical Oncology. 35(15_suppl). TPS2616–TPS2616. 2 indexed citations
7.
8.
Bisconte, Angelina, et al.. (2016). A new treatment for autoimmune blistering diseases- the efficacy of Bruton's tyrosinase kinase inhibitor PRN473 in canine pemphigus foliaceus. 2 indexed citations
9.
Wlasichuk, Kenneth B., Li Tan, Yushen Guo, et al.. (2015). Determination of equilibrium constant of amino carbamate adduct formation in sisomicin by a high pH based high performance liquid chromatography. Journal of Pharmaceutical and Biomedical Analysis. 111. 126–130. 2 indexed citations
10.
Tan, Li, et al.. (2012). A high pH based reversed-phase high performance liquid chromatographic method for the analysis of aminoglycoside plazomicin and its impurities. Journal of Pharmaceutical and Biomedical Analysis. 66. 75–84. 7 indexed citations
11.
Higgins, Deborah L., Ray Chang, Dmitri Debabov, et al.. (2005). Telavancin, a Multifunctional Lipoglycopeptide, Disrupts both Cell Wall Synthesis and Cell Membrane Integrity in Methicillin-Resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy. 49(3). 1127–1134. 356 indexed citations
12.
Cass, Robert, et al.. (2004). Increasing the efficiency of pharmacokinetic sample procurement, preparation and analysis by liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry. 18(10). 1066–1072. 3 indexed citations
13.
Leadbetter, Michael R., Dane E. Karr, Kevin M. Krause, et al.. (2004). Hydrophobic Vancomycin Derivatives with Improved ADME Properties: Discovery of Telavancin (TD-6424). The Journal of Antibiotics. 57(5). 326–336. 126 indexed citations
14.
15.
Danis, Paul O., et al.. (1996). Methods for the Analysis of Hydrocarbon Polymers by Matrix-assisted Laser Desorption/Ionization Time-of-flight Mass Spectrometry. Rapid Communications in Mass Spectrometry. 10(7). 862–868. 48 indexed citations
16.
Karr, Dane E. & Clifford C. Walters. (1996). Sterane Biomarker Analysis via Ion Trap Mass Spectrometry. Rapid Communications in Mass Spectrometry. 10(9). 1088–1092. 1 indexed citations
17.
Danis, Paul O. & Dane E. Karr. (1993). A facile sample preparation for the analysis of synthetic organic polymers by matrix‐assisted laser desorption/ionization. Organic Mass Spectrometry. 28(8). 923–925. 150 indexed citations
18.
Moss, C W, W F Bibb, Dane E. Karr, G O Guerrant, & M A Lambert. (1983). Cellular fatty acid composition and ubiquinone content of Legionella feeleii sp. nov. Journal of Clinical Microbiology. 18(4). 917–919. 25 indexed citations
19.
Karr, Dane E., W F Bibb, & William O. Moss. (1982). Isoprenoid Quinones oftheGenusLegionella. 3 indexed citations
20.
Karr, Dane E., et al.. (1981). Cellular Fatty Acid Composition of Legionella longbeachae sp. nov. Journal of Clinical Microbiology. 14(6). 692–694. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Keiko Tabei Breakdown of academic impact, for papers by Aleš Štrancar Breakdown of academic impact, for papers by John Chapman Breakdown of academic impact, for papers by T. William Hutchens Breakdown of academic impact, for papers by Dominique J. Wiener Breakdown of academic impact, for papers by Hugo D. Meiring Breakdown of academic impact, for papers by Matthew Zimmerman Breakdown of academic impact, for papers by S. Jönsson Breakdown of academic impact, for papers by Lene Jakobsen Breakdown of academic impact, for papers by Ruchi Pandey
Rankless by CCL
2026